Search
Search Results
##search.searchResults.foundPlural##
-
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4580Suppl. Files: 1243PDF: 1152Html: 307 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3572PDF: 1358HTML: 2400Fi.1 Gritti.Rambaldi: 257 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2396PDF: 1879HTML: 1009 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2284PDF: 2011HTML: 533 -
Magnusiomyces capitatus Breakthrough Infection in Allogeneic Hematopoietic Cell Transplant Recipients Receiving Echinocandin Prophylaxis: Clinical Features, Management, and Review of the Literature
96PDF: 156Suppl. Files: 20Html: 105Html Suppl. Files: 80 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
2211PDF: 1173HTML: 10764Untitled: 238 -
-
THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
2344PDF: 1012HTML: 6865Figure 1: 212 -
DIAGNOSIS OF MALARIA INFECTION WITH OR WITHOUT DISEASE
3746PDF: 1181HTML: 23382 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2602PDF: 1014HTML: 388 -
DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
4966PDF: 1925HTML: 2200 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1405PDF: 1114HTML: 446 -
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
2054PDF: 870HTML: 2224Table 1: 227Table 2: 243Table 3: 239Table 4: 235Table 5: 234Tble 6: 230Cover Letter: 244Greene Tab.7: 250 -
BACTERIAL INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
3367PDF: 1939HTML: 3708 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1708PDF: 1128HTML: 496 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4717PDF: 1718HTML: 4315Tables and Images: 282 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3016PDF: 1033HTML: 7516 -
-
-
-
APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
2721PDF: 1031HTML: 15140 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3511PDF: 2082HTML: 7583 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4094PDF: 1122HTML: 3908Untitled: 200Cneo. Fig.1: 142Untitled: 133Untitled: 160Untitled: 169 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1887PDF: 935HTML: 1541 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
586PDF: 608Suppl. Files: 79HTML: 168 -
ASSOCIATION BETWEEN PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE INFECTION PRE-ADMISSION 48-HOUR FEVER BURDEN AND OUTCOMES IN PEDIATRIC MYCOPLASMA PNEUMONIAE
268PDF: 385Suppl. Files: 75HTML: 184 -
-
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2678PDF: 1666HTML: 720 -
IDENTİFİCATİON OF LEİSHMANİA TROPİCA FROM PEDİATRİC VİSCERAL LEİSHMANİASİS İN SOUTHERN MEDITERRANEAN REGION OF TURKEY. Molecular characterization of pediatric visceral leishmaniasis
1161PDF: 770HTML: 287 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2363PDF: 935HTML: 2021Fig 1 Rossi: 243 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2391PDF: 630HTML: 377







